Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

Compare

584 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMLX Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Amylyx

Pharmaceuticals Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMLX Stock 12 Month Forecast

Average Price Target

$12.17

▲(85.24%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Amylyx Pharmaceuticals Inc in the last 3 months. The average price target is $12.17 with a high forecast of $17.00 and a low forecast of $8.00. The average price target represents a 85.24% change from the last price of $6.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,6.015384615384615,6.930769230769231,7.846153846153846,8.76153846153846,9.676923076923078,10.592307692307692,11.507692307692308,12.423076923076923,13.338461538461539,14.253846153846155,15.16923076923077,16.084615384615383,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.6438461538461535,6.187692307692307,6.731538461538461,7.275384615384615,7.819230769230769,8.363076923076923,8.906923076923077,9.45076923076923,9.994615384615384,10.538461538461538,11.082307692307692,11.626153846153846,{"y":12.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.1,5.323076923076923,5.546153846153846,5.769230769230769,5.992307692307692,6.2153846153846155,6.438461538461539,6.661538461538461,6.884615384615385,7.107692307692307,7.330769230769231,7.553846153846154,7.776923076923077,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.71,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$12.17

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$6.5

Hold

-1.07%

Downside

Reiterated

06/25/25

Amylyx Pharmaceuticals' stock score is primarily impacted by its financial performance, which reveals significant challenges, including declining revenues and cash flow issues. However, strong technical indicators and positive developments from the earnings call provide some balance, indicating potential for future growth amid current operational struggles.

Seamus FernandezGuggenheim

Guggenheim

$17

Buy

158.75%

Upside

Initiated

06/24/25

Amylyx initiated with a Buy at GuggenheimAmylyx initiated with a Buy at Guggenheim

Geoff MeachamCiti

Citi

$12

Buy

82.65%

Upside

Initiated

06/18/25

Amylyx initiated with a Buy at CitiAmylyx initiated with a Buy at Citi

Andrew FeinH.C. Wainwright

H.C. Wainwright

$16

Buy

143.53%

Upside

Reiterated

06/11/25

Optimistic Buy Rating for Amylyx Pharmaceuticals' AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights

Joseph ThomeTD Cowen

TD Cowen

―

Buy

―

Initiated

05/30/25

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from TD Cowen

Charlie CY YangBank of America Securities

Bank of America Securities

$10

Buy

52.21%

Upside

Reiterated

05/14/25

Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Bank of America Securities

Graig SuvannavejhMizuho Securities

Mizuho Securities

$7→$8

Buy

21.77%

Upside

Reiterated

05/14/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Marc GoodmanLeerink Partners

Leerink Partners

$4→$10

Buy

52.21%

Upside

Reiterated

05/09/25

Amylyx upgraded to Outperform from Market Perform at LeerinkAmylyx upgraded to Outperform from Market Perform at Leerink

Corinne JohnsonGoldman Sachs

Goldman Sachs

Hold

-23.90%

Downside

Reiterated

11/21/24

Goldman Sachs reiterates Neutral Rating on Amylyx Pharmaceuticals inc. (AMLX)Goldman Sachs analyst Corinne Jenkins reiterated a Neutral rating and $5.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX)

Joel BeattyRobert W. Baird

Robert W. Baird

$3→$11

Buy

67.43%

Upside

Upgraded

11/18/24

Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$6.5

Hold

-1.07%

Downside

Reiterated

06/25/25

Seamus FernandezGuggenheim

Guggenheim

$17

Buy

158.75%

Upside

Initiated

06/24/25

Amylyx initiated with a Buy at GuggenheimAmylyx initiated with a Buy at Guggenheim

Geoff MeachamCiti

Citi

$12

Buy

82.65%

Upside

Initiated

06/18/25

Amylyx initiated with a Buy at CitiAmylyx initiated with a Buy at Citi

Andrew FeinH.C. Wainwright

H.C. Wainwright

$16

Buy

143.53%

Upside

Reiterated

06/11/25

Optimistic Buy Rating for Amylyx Pharmaceuticals' AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights

Joseph ThomeTD Cowen

TD Cowen

―

Buy

―

Initiated

05/30/25

Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from TD Cowen

Charlie CY YangBank of America Securities

Bank of America Securities

$10

Buy

52.21%

Upside

Reiterated

05/14/25

Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Bank of America Securities

Graig SuvannavejhMizuho Securities

Mizuho Securities

$7→$8

Buy

21.77%

Upside

Reiterated

05/14/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Marc GoodmanLeerink Partners

Leerink Partners

$4→$10

Buy

52.21%

Upside

Reiterated

05/09/25

Amylyx upgraded to Outperform from Market Perform at LeerinkAmylyx upgraded to Outperform from Market Perform at Leerink

Corinne JohnsonGoldman Sachs

Goldman Sachs

Hold

-23.90%

Downside

Reiterated

11/21/24

Joel BeattyRobert W. Baird

Robert W. Baird

$3→$11

Buy

67.43%

Upside

Upgraded

11/18/24

Strong Buy Rating for Amylyx Pharmaceuticals Inc. Driven by Promising Avexitide Prospects and Stable Financial Standing

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amylyx Pharmaceuticals Inc

1 Month

xxx

Success Rate

8/16 ratings generated profit

Average Return

-0.34%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.34% per trade.

3 Months

xxx

Success Rate

9/16 ratings generated profit

Average Return

+22.09%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +22.09% per trade.

1 Year

Andrew FeinH.C. Wainwright

Success Rate

11/18 ratings generated profit

Average Return

+36.32%

reiterated a buy rating 24 days ago

Copying Andrew Fein's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +36.32% per trade.

2 Years

xxx

Success Rate

11/18 ratings generated profit

Average Return

+59.06%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 61.11% of your transactions generating a profit, with an average return of +59.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMLX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMLX has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AMLX average Analyst price target in the past 3 months is 12.17.

Each month's total comprises the sum of three months' worth of ratings.

AMLX Financial Forecast

AMLX Earnings Forecast

Next quarter’s earnings estimate for AMLX is -$0.46 with a range of -$0.53 to -$0.39. The previous quarter’s EPS was -$0.42. AMLX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.

AMLX Sales Forecast

Next quarter’s sales forecast for AMLX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AMLX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 57.81% of the time in the same period. In the last calendar year AMLX has Outperformed its overall industry.

AMLX Stock Forecast FAQ

What is AMLX’s average 12-month price target, according to analysts?

Based on analyst ratings, Amylyx Pharmaceuticals Inc’s 12-month average price target is 12.17.

What is AMLX’s upside potential, based on the analysts’ average price target?

Amylyx Pharmaceuticals Inc has 85.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AMLX a Buy, Sell or Hold?

Amylyx Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Amylyx Pharmaceuticals Inc’s price target?

The average price target for Amylyx Pharmaceuticals Inc is 12.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $8.00. The average price target represents 85.24% Increase from the current price of $6.57.

What do analysts say about Amylyx Pharmaceuticals Inc?

Amylyx Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of AMLX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Amylyx Pharmaceuticals Inc (AMLX) Stock Forecast & Price Target

AMLX Analyst Ratings

AMLX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amylyx Pharmaceuticals Inc

AMLX Analyst Recommendation Trends

AMLX Financial Forecast

AMLX Earnings Forecast

AMLX Sales Forecast

AMLX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts